CENTESSA PHARMACEUTICA

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

10 дек 2023 12:05:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

13 ноя 2023 16:05:10 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

02 ноя 2023 09:09:52 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

31 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

30 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

25 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

03 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

31 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

23 авг 2023 17:08:51 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

14 авг 2023 07:00:30 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

10 июл 2023 08:00:04 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

24 май 2023 08:00:09 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

22 май 2023 07:00:21 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

12 май 2023 07:00:06 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

30 мар 2023 07:00:28 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

27 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

01 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

06 фев 2023 08:00:00 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

26 янв 2023 09:08:14 Источник Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

10 дек 2022 15:30:29 Источник Nasdaq GlobeNewswire